Xenon Pharmaceuticals (NASDAQ:XENE) CFO Purchases $559,800.00 in Stock

Posted by Brian Himes on Oct 4th, 2026

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) CFO Thomas Patrick Kelly bought 15,000 shares of the company’s stock in a transaction on Wednesday, September 30th. The shares were acquired at an average cost of $37.32 per share, for a total transaction of $559,800.00. Following the completion of the acquisition, the chief financial officer directly owned 15,000 shares of the company’s stock, valued at $559,800. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock opened at $38.02 on Friday. Xenon Pharmaceuticals Inc. has a 1 year low of $36.07 and a 1 year high of $72.66. The firm’s 50-day moving average is $56.32 and its 200-day moving average is $57.02. The company has a market cap of $3.68 billion, a P/E ratio of -8.02 and a beta of 0.60.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.05. During the same quarter in the prior year, the company posted ($1.07) EPS. As a group, sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -4.7 earnings per share for the current year.

Institutional Trading of Xenon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $454,057,000. Avoro Capital Advisors LLC raised its holdings in Xenon Pharmaceuticals by 0.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after purchasing an additional 24,444 shares in the last quarter. Jupiter Topco LLC acquired a new stake in Xenon Pharmaceuticals in the second quarter worth approximately $252,673,000. Janus Henderson Group PLC boosted its stake in Xenon Pharmaceuticals by 2.3% during the 1st quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock valued at $242,858,000 after purchasing an additional 91,948 shares in the last quarter. Finally, Capital International Investors boosted its stake in Xenon Pharmaceuticals by 7.3% during the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock valued at $153,058,000 after purchasing an additional 233,466 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Needham & Company LLC dropped their price target on Xenon Pharmaceuticals from $78.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, September 18th. HC Wainwright restated a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Friday, September 18th. Wells Fargo & Company dropped their target price on Xenon Pharmaceuticals from $69.00 to $64.00 and set an “overweight” rating on the stock in a research report on Friday, September 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Finally, Royal Bank Of Canada lowered their price target on shares of Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, September 18th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $70.27.

Read Our Latest Analysis on Xenon Pharmaceuticals

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

Positive Sentiment: CEO Ian Mortimer purchased 30,000 shares for approximately $1.12 million, while CFO Thomas Patrick Kelly bought 15,000 shares for about $559,800. The combined purchases, made near $37 per share, may reassure investors that senior management views the recent weakness as an attractive entry point. Insider Buying: Xenon Pharmaceuticals CFO Buys $559,800 in Stock
Positive Sentiment: RBC said safety issues are unlikely to derail the approval path for azetukalner (XEN1101), Xenon’s lead investigational treatment for epilepsy and major depressive disorder. This reduces concern that safety questions could materially delay a key development catalyst. Xenon’s AZK Approval Path Unlikely to Be Hurt by Safety Issues
Neutral Sentiment: Xenon granted eight newly hired, non-officer employees 17,850 stock options and 10,500 restricted share units under Nasdaq’s inducement-grant exemption. The awards support recruitment but could modestly increase future share dilution. Xenon Pharmaceuticals Reports Inducement Grants
Negative Sentiment: Although analysts maintain a broadly positive consensus, recent target-price reductions—including Deutsche Bank’s cut to $46 from $90—highlight continuing concerns about valuation, execution and the path to commercialization. Xenon remains loss-making, with analysts expecting a full-year loss of approximately $4.70 per share.

About Xenon Pharmaceuticals

(Get Free Report)

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses research in ion channels and neuronal signaling to identify potential treatments for conditions with significant unmet medical needs.

Xenon’s lead investigational medicine is azetukalner, also known as XEN1101, a selective potassium channel opener being evaluated for epilepsy and major depressive disorder. The company is also advancing additional programs aimed at genetically defined epilepsies and other disorders of the central nervous system.